Search results
Time to Sell These 3 Under-Performing Stocks Based on Their Bad Decisions
InvestorPlace· 3 hours agoThe classic example of this phenomenon is Blockbuster’s failure to acquire Netflix (NASDAQ:NFLX)...
Apple, Amazon, Nvidia and Tesla are part of Zacks Earnings Preview
Zacks via Yahoo Finance· 3 hours agoBut it isn’t surprising as both companies’ results proved better than what market participants had...
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
Motley Fool via Yahoo Finance· 2 days agoZepbound's performance was equally impressive, with the obesity medication generating more than $500...
Tiny Telehealth Stock Sinks 85% as IPO Rally Collapses
Bloomberg via Yahoo Finance· 44 minutes ago(Bloomberg) -- The Singaporean telehealth provider Mobile-Health Network Solutions, once the...
Oscar Best Picture Winner ‘Oppenheimer’ Is No. 5 In Deadline’s 2023 Most Valuable Blockbuster...
Deadline Hollywood· 5 days agoDeadline’s Most Valuable Blockbuster tournament is back. While studios during Covid wildly embraced...
Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price...
Business Insider· 3 days agoSales of Wegovy more than doubled in the first quarter year-on-year, to $1.3 billion.
Investors Pile Into Amgen in Search of Next Obesity Drug Payout
Bloomberg via Yahoo Finance· 2 hours ago(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo...
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Reuters via Yahoo Finance· 4 days agoIts lone approved skin cancer drug, Libtayo, brought in sales of $264 million, which came ahead of...
Disney Detonates Four Bombs In Deadline’s 2023 Most Valuable Blockbuster Tournament
Deadline Hollywood· 4 days agoDeadline’s Most Valuable Blockbuster tournament is back. While studios during Covid wildly embraced...
‘Spider-Man: Across The Spider-Verse’ Conquers Superhero Fatigue At No. 3 In Deadline’s 2023 Most...
Deadline Hollywood· 3 days ago'Spider-Man: Across the Spider-Verse' conquers superhero fatigue at no. 3 in Deadline’s 2023 Most...